If your favorite internet doctor seems to have a weirdly intense vendetta against compounded or non-branded GLP-1s, a new Washington Post investigation may help explain part of the environment they are operating in. The paper found Eli Lilly and Novo Nordisk spent more than $270 million promoting their diabetes and obesity drugs since 2018, with payment…